[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549906":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":40,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Medical University of Lublin","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","SCLEROSTIN","Pathogenesis of mastocytosis bone disease",[14],{"name":15,"affiliation":5,"role":16},"Aneta A Szudy-Szczyrek, MD., PhD.","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Aneta Szudy-Szczyrek, MD., PhD.","CONTACT","+48815345468","aneta.szudy-szczyrek@umlub.pl",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Department of Hematooncology and Bone Marrow Transplantation","RECRUITING","Lublin","Lublin Voivodeship","20-081","Poland","PL",{"type":33,"coordinates":34},"Point",[35,36],22.57009,51.25058,{"lat":36,"lon":35},[39],{"name":19,"role":20,"phone":7,"phoneExt":7,"email":22},{"type":16,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Aneta Szudy Szczyrek","Doctor of Medicine","100549906","relationship-between-circulating-sclerostin-and-bone-lesions-in-patients-with-mastocytosis-100549906",false,"NCT06440148","Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis","Role of Sclerostin in Mastocytosis Bone Disease","Inclusion Criteria:\n\n* Age \\> 18 years\n* Mastocytosis defined according to WHO criteria\n* Known KIT mutation status\n\nExclusion Criteria:\n\n* History of organ transplant\n* Inability to give informed consent\n* Pregnancy, Breastfeeding\n* Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection",true,"ALL","18 Years",{"count":54,"type":55},50,"ESTIMATED","OBSERVATIONAL","Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues.\n\nBones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.",[59,60],"Mastocytosis","Bones",[60,59,62,63,64],"Osteolysis","Osteosclerosis","Sclerostin","2024-05-28",{"date":67,"type":68},"2024-06-03","ACTUAL",{"date":70,"type":68},"2019-09-01",{"date":72,"type":55},"2026-12-31",{"name":5,"class":6},1]